What Are The Expected Market Size, Growth, and Trends for the Global Enbrel (Etanercept) Market by 2025?
The Enbrel (Etanercept) market size has witnessed significant growth in recent years and is expected to further grow from $16,641.47 million in 2024 to $17,701.87 million in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the approval for multiple indications, strong physician adoption, introduction of patient-friendly injection devices, increased healthcare focus on cost-effective treatments for chronic diseases, extensive clinical trials and positive outcomes.
The market is projected to continue its robust growth, reaching $22,351.29 million in 2029 at a CAGR of 6.0%. The expected growth in the forecast period can be attributed to the aging global population, increasing prevalence of autoimmune diseases, increasing preference for biologics, introduction of biosimilars, increasing government funding and insurance coverage. Major trends in the forecast period include utilization in pediatric populations, rise in home-based treatments, digital health integration, combination therapy approaches, and advances in genomics and biomarker research.
Acquire Your Free Sample of The Global Enbrel (Etanercept) Global Market Report 2025 Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19899&type=smp
What Drives the Growth of the Enbrel (Etanercept) Global Market?
The enbrel (etanercept) market growth is propelled by the surging prevalence of autoimmune conditions. Autoimmune conditions occur when the body’s immune system erroneously targets and attacks its own healthy tissues. The rising prevalence of these conditions is driven by factors such as genetic susceptibility, the hygiene hypothesis, environmental triggers, and improved diagnosis and awareness. Enbrel is effective in treating various autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis by inhibiting tumor necrosis factor-alpha (TNF-a), a crucial protein in immune and inflammatory responses, thereby reducing inflammation, alleviating symptoms, and slowing the progression of these conditions.
How is the Enbrel (Etanercept) Global Market Segmented?
The enbrel (etanercept) market is divided into the following segments:
1) By Product: Brands Drugs; Biosimilar Drugs
2) By Form: Liquid Solution; Powder For Injections
3) By Application: Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Juvenile Idiopathic Arthritis
Access the detailed report here:
https://www.thebusinessresearchcompany.com/report/enbrel-etanercept-global-market-report
Who are the Major Players in the Enbrel (Etanercept) Global Market?
Prominent companies operating in the enbrel (etanercept) market include Amgen Inc and Pfizer Inc.
What are the Emerging Market Trends for Enbrel (Etanercept)?
Innovative product development, such as TNF inhibitors, is key trend in the Enbrel (etanercept) market. These TNF inhibitors target and block tumor necrosis factor (TNF), a protein that plays a pivotal role in inflammation, hence managing autoimmune diseases. For instance, in October 2023, Amgen Inc., a US-based biotechnology company, announced the U.S. Food and Drug Administration approval for Enbrel (etanercept) for the management of children aged two and up who have active juvenile psoriatic arthritis (JPsA).
Which Regional Markets Hold the Largest and Fastest-Growing Market Shares?
In 2024, North America held the largest share of the global enbrel (etanercept) market, while Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The Enbrel (Etanercept) Global Market Report 2025 Offer?
Enbrel (etanercept) is a biologic medication used to treat various autoimmune conditions by inhibiting the activity of tumor necrosis factor (TNF), a protein that plays a key role in inflammation. It is a synthetic form of a naturally occurring protein in the body, designed to bind to TNF and prevent it from binding to its receptors, thereby reducing inflammation. It is typically administered via a subcutaneous injection, either by a healthcare provider or by patients themselves at home. The Enbrel (Etanercept) Global Market Report 2025 research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Unlock valuable market insights by purchasing the exclusive report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19899
About The Business Research Company
The Business Research Company is renowned for its comprehensive reports from 27 industries covering over 60 geographies, built with over 1,500,000 datasets. With in-depth secondary research and unique insights from industry leaders, you have the information you need to stay ahead. Our flagship product, the Global Market Model, delivers comprehensive and updated forecasts to enable informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model